EGFR-mutant NSCLC
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
June, 2024
June 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
« May
EGFR-mutant NSCLC
Jun 21, 2024, 10:50 |
Blog
Out in JCO the groundbreaking results of the randomized phase 3 trial PALOMA-3 study
Antonio Passaro, Medical Oncologist at the European Institute of Oncology, shared on LinkedIn: "Out in…
Jun 2, 2024, 15:18 |
Blog
Chul Kim: PALOMA-3 trial: Significant reduction in IRRs with SC vs. IV in EFGR + NSCLC
Chul Kim, Thoracic Medical Oncologist at Georgetown University, shared a post on X: "PALOMA-3 trial: SC…
Apr 26, 2024, 09:26 |
Insight
Chul Kim: Thoughtful discussion and great talk by Rachel Sanborn about recent approval of FLAURA2
Chul Kim, Thoracic Medical Oncologist at Georgetown University, shared a post on X/Twitter: ''First-line treatment…
All:
3
Posts:
1 - 10
Eliot Levitt: The Yvonne Awards demonstrate something that it doesn't hurt to be reminded of
New data from the NEST clinical trial was presented at ESMOGI24 - Agenus
Zainab Shinkafi-Bagudu's latest commentary on Cervical Cancer Elimination Forum
New Paper Alert! Amivantamab-Lazertinib Improves Outcomes in High-Risk EGFR-Mutant NSCLC Subgroups: MARIPOSA Study Results
Learn more about overcoming barriers to immunotherapy for microsatellite stable colorectal cancer
Facebook
RSS Feed
Twitter
Linkedin
Youtube